Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW677954 in overweight dyslipidaemic subjects
2005-001558-26Phase 2Completed
- Sponsor
- GSK
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of saroglitazar in lipid disorder and Overweight (5 arms), sponsored by GSK. Primary endpoint: Percentage change from baseline in non-HDL cholesterol at 24 weeks. Started Sep 2005; status: completed.
02
Drugs
saroglitazar
03
Conditions
lipid disorderOverweight
Beyond the preview
Go deeper on 2005-001558-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001558-26.